Revenue (Details) $ in Thousands, £ in Millions |
1 Months Ended | 6 Months Ended | 12 Months Ended | ||||
|---|---|---|---|---|---|---|---|
|
Jun. 30, 2014
GBP (£)
|
Jun. 30, 2014
USD ($)
|
Dec. 31, 2015
USD ($)
item
|
Dec. 31, 2015
USD ($)
|
Jun. 30, 2015
USD ($)
|
Jun. 30, 2014
USD ($)
|
Jun. 30, 2013
USD ($)
|
|
| Collaboration and License Agreement | |||||||
| Revenue recognized | $ 8,979 | $ 9,871 | $ 825 | ||||
| Collaborative arrangement | GlaxoSmithKline Intellectual Property Development Ltd | |||||||
| Collaboration and License Agreement | |||||||
| Number of additional target peptides, that the entity has right to nominate | item | 4 | ||||||
| Upfront payment received | £ 25 | $ 42,100 | |||||
| Milestone payments received | $ 10,800 | 7,200 | |||||
| Royalties received | $ 0 | ||||||
| Written notice period required to be served for the termination of agreement for material breach (in days) | 60 days | ||||||
| Notice period required to be served for the termination of agreement or specific program (in days) | 60 days | ||||||
| Maximum combination studies permitted | item | 8 | ||||||
| Revenue recognized | $ 8,979 | $ 9,871 | $ 825 | $ 0 | |||
| X | ||||||||||
- Definition The number of additional target peptides the counterparty has right to nominate, excluding those where the entity has already initiated development of certain candidates. No definition available.
|
| X | ||||||||||
- Definition Term of the notice period for termination of license agreement or specific license or collaboration program. No definition available.
|
| X | ||||||||||
- Definition Represents cash received upon achievement of various development milestones under license agreements. No definition available.
|
| X | ||||||||||
- Definition Term of the written notice period for termination of license agreement for material breach. No definition available.
|
| X | ||||||||||
- Definition Number of combination studies that can be performed using the entity's therapies. No definition available.
|
| X | ||||||||||
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. No definition available.
|
| X | ||||||||||
- Definition Cash received from licensees for license fees during the current period. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Revenue earned during the period from the leasing or otherwise lending to a third party the entity's rights or title to certain property. Royalty revenue is derived from a percentage or stated amount of sales proceeds or revenue generated by the third party using the entity's property. Examples of property from which royalties may be derived include patents and oil and mineral rights. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Total revenue from sale of goods and services rendered during the reporting period, in the normal course of business, reduced by sales returns and allowances, and sales discounts. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|